NRX Pharmaceuticals Inc (NRXP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NRX Pharmaceuticals Inc (NRXP) has a cash flow conversion efficiency ratio of 0.112x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.89 Million) by net assets ($-25.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NRX Pharmaceuticals Inc market cap and net worth for the company's overall valuation and market capitalisation.
NRX Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how NRX Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NRX Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NRX Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore NRX Pharmaceuticals Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Perak Transit Bhd
KLSE:0186
|
-0.003x |
|
Forum Markets, Incorporated
NASDAQ:FRMM
|
-0.121x |
|
Dutaland Bhd
KLSE:3948
|
-0.019x |
|
T7 Global Bhd
KLSE:7228
|
0.023x |
|
K Wave Media Ltd.
NASDAQ:KWM
|
655.501x |
|
Wintao Communications Co. Ltd
SHE:301139
|
0.002x |
|
Access Bio Inc
KQ:950130
|
-0.015x |
|
GreenMobility A/S
CO:GREENM
|
0.802x |
Annual Cash Flow Conversion Efficiency for NRX Pharmaceuticals Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of NRX Pharmaceuticals Inc from 2017 to 2024. View latest NRX Pharmaceuticals Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-23.22 Million | $-10.64 Million | 0.458x | -75.19% |
| 2023-12-31 | $-11.73 Million | $-21.66 Million | 1.846x | +134.40% |
| 2022-12-31 | $7.41 Million | $-39.76 Million | -5.366x | -196.10% |
| 2021-12-31 | $20.81 Million | $-37.70 Million | -1.812x | -3601.91% |
| 2020-12-31 | $-43.77 Million | $-2.27 Million | 0.052x | +292.57% |
| 2019-12-31 | $29.50 Million | $-792.73K | -0.027x | -294.90% |
| 2018-12-31 | $69.54 Million | $-473.19K | -0.007x | -248.09% |
| 2017-12-31 | $69.47 Million | $-135.81K | -0.002x | -- |
About NRX Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in p… Read more